Search

316 Result(s)
Sort by

LastMile – improving through digital

LastMile – improving through digital

LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
cystic fibrosis phase II trial

cystic fibrosis phase II trial

The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Soaring to save lives

Soaring to save lives

Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Netherton syndrome (NS)

Netherton syndrome (NS)

Information on Netherton syndrome (NS), a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
FOYA_Shanghai

FOYA_Shanghai

Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Making sustainable medicines through eco-design

Making sustainable medicines through eco-design

Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle